1582. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year

BACKGROUND: The first long-acting (LA) antiretroviral therapy (ART) regimen, cabotegravir+rilpivirine (CAB+RPV) injection, was approved by the FDA in January 2021 for ART-experienced, people with HIV (PWH) with undetectable viral load (VL< 50 copies/mL). We assessed clinical effectiveness of CAB+...

Descripción completa

Detalles Bibliográficos
Autores principales: Sension, Michael G, Hsu, Ricky K, Fusco, Jennifer S, Brunet, Laurence, Cochran, Quateka, Uranaka, Christine, Sridhar, Gayathri, Vannappagari, Vani, Zolopa, Andrew, van Wyk, Jean A, McCurdy, Lewis, Fusco, Gregory P, Wohlfeiler, Michael B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752331/
http://dx.doi.org/10.1093/ofid/ofac492.105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752331/
http://dx.doi.org/10.1093/ofid/ofac492.105

Ejemplares similares